Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) generates news as a clinical-stage biotechnology company focused on oncology medicines that target genetically determined dependencies within the chromatin regulatory system. Its updates frequently highlight progress from the Gene Traffic Control® platform, which systematically identifies and validates chromatin-based targets for small-molecule inhibitors and protein degraders.
News about FHTX often centers on its lead clinical candidate FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor being evaluated in a Phase 1 multi-center dose-escalation trial for SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population. Press releases describe preclinical data, trial enrollment status, and combination strategies with standard-of-care chemotherapies, pembrolizumab, and KRAS inhibitors in NSCLC models.
Investors following FHTX can also expect regular announcements on Foghorn’s selective degrader programs. These include a selective CBP degrader with potential in EP300-mutant cancers and ER+ breast cancer, a selective EP300 degrader for hematologic malignancies such as multiple myeloma and diffuse large B-cell lymphoma, and a selective ARID1B degrader for ARID1A-mutated solid tumors. Company communications summarize preclinical efficacy, tolerability, and formulation advances, as well as milestones such as progression into toxicology or IND-enabling studies.
Another recurring theme in Foghorn’s news flow is corporate and financial activity. Releases discuss collaboration revenue from its strategic partnership with Lilly, cash and marketable securities levels, and equity financings conducted under a shelf registration statement on Form S-3, including a registered direct financing that raised approximately $50 million in gross proceeds. Updates on leadership changes in the finance function and participation in healthcare and investor conferences also appear in FHTX news.
By monitoring this news page, readers can review company-issued information on trial progress, preclinical data, financing transactions, collaborations, and corporate developments that shape the ongoing story of Foghorn Therapeutics’ chromatin-focused oncology pipeline.
Foghorn Therapeutics (Nasdaq: FHTX) announced management will participate in two investor conferences: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. EDT and The Citizens Life Sciences Conference on March 11, 2026 at 11:20 a.m. EDT.
Adrian Gottschalk, President and CEO, will present at both events and take one-on-one meetings. A webcast of the TD Cowen presentation will be available in the company investors section for 90 days.
Foghorn Therapeutics (Nasdaq: FHTX) appointed Ryan Maynard as Chief Financial Officer effective February 23, 2026. Mr. Maynard brings over 25 years of biopharma financial leadership, has raised over $1 billion, and led financings and commercial launch planning for approved therapies.
The company noted Maynard’s prior roles at Cara Therapeutics, Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics, his recent transactional work including a $37.5M non-dilutive royalty arrangement, and his board seat at Iovance.
Foghorn Therapeutics (Nasdaq: FHTX) announced management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The company presentation is scheduled for Wednesday, February 11, 2026 at 3:00 p.m. EST by Adrian Gottschalk, President and CEO.
A live webcast will be available via the company’s Investors "Events & Presentations" page and will remain accessible for 30 days. Management will also conduct one-on-one meetings at the summit.
Foghorn Therapeutics (Nasdaq: FHTX) closed a $50 million registered direct financing on Jan 13, 2026, selling common stock and warrants.
The company sold 2,030,314 common shares at $6.71 per share (a 30% premium to the Jan 9, 2026 Nasdaq price), issued pre-funded warrants for up to 5,421,250 shares at $6.7099, and issued series warrants to buy 3,725,782 shares at $13.42 and another 3,725,782 shares at $20.13. Gross proceeds were approximately $50 million (excluding any proceeds from potential warrant exercises). The financing was sold directly by Foghorn without an underwriter and included participation by BVF Partners, Deerfield Management, Flagship Pioneering and a leading biotech mutual fund.
Foghorn Therapeutics (Nasdaq: FHTX) announced a $50.0 million equity financing led by BVF Partners, Deerfield Management, Flagship Pioneering and a biotech mutual fund, expected to close Jan 13, 2026. The company reported an estimated $208.9 million in cash, cash equivalents, and marketable securities inclusive of the financing, extending runway into the first half of 2028. Clinical and preclinical progress includes an on‑track Phase 1 dose‑escalation trial of FHD‑909 in SMARCA4‑mutant NSCLC, and IND‑tracking selective degrader programs for CBP, EP300, and ARID1B with IND/enabling milestones anticipated in 2026.
Foghorn Therapeutics (Nasdaq: FHTX) announced that management will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, FL, December 2-4, 2025.
The company said a Fireside Chat with Adrian Gottschalk, president and CEO, is scheduled for Thursday, December 4, 2025 at 9:10 a.m. EST. Management will also hold one-on-one meetings. A webcast of the presentation will be available under Events & Presentations on the company website and will be accessible for 30 days.
Foghorn Therapeutics (NASDAQ: FHTX) provided its Q3 2025 financial and corporate update on Nov 5, 2025, reporting continued clinical and preclinical progress across multiple degrader programs and a strong balance sheet.
Key items include $180.3M in cash, cash equivalents, and marketable securities as of Sept 30, 2025 (cash runway into 2028); FHD-909 Phase 1 dose-escalation trial enrolling with NSCLC as the primary target; Selective CBP degrader entering non-GLP toxicology in Q4 2025 and anticipated IND-ready in 2026; Selective EP300 degrader showing broad preclinical activity (over 70% of heme sub-lineages) and IND-enabling studies expected in 2026; Selective ARID1B degrader advancing toward in vivo proof-of-concept in 2026. CFO Kristian Humer will depart Nov 14, 2025.
Foghorn Therapeutics (Nasdaq: FHTX) announced management will participate in three investor conferences in November 2025: Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference.
Fireside chat dates and times: Guggenheim Nov 10, 2025 at 11:00 AM ET; Stifel Nov 13, 2025 at 4:00 PM ET; Jefferies London Nov 19, 2025 at 10:30 AM GMT. Presenter: Adrian Gottschalk, President and CEO. Webcasts will be available in Investors > Events & Presentations on the company site for 90 days.
Foghorn Therapeutics (NASDAQ: FHTX) reported preclinical progress for three selective degrader programs and will host a virtual investor event on October 30, 2025 at 12:00 p.m. ET. Key advances: a first-in-class Selective ARID1B degrader achieving selective degradation and downstream gene modulation with in vivo proof-of-concept targeted for 2026; a Selective CBP degrader (CBPd-171) entering non-GLP toxicology in Q4 2025 and targeting IND-readiness in 2026 with an optimized long-acting injectable; and a Selective EP300 degrader showing broad heme activity (>70% sub-lineages) and favorable tolerability in multiple myeloma models.
Foghorn Therapeutics (Nasdaq: FHTX) announced presentation and investor event updates on its targeted protein degrader programs. A Keynote Plenary presentation on the Selective ARID1B degrader will be delivered on Oct 29, 2025 at 3:45 p.m. EDT at the 8th Annual TPD and Induced Proximity Summit in Boston.
Foghorn will host a virtual investor event on Oct 30, 2025 at 12 p.m. EDT to review pipeline updates for the Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, including progress toward IND‑enabling studies. The presentation and replay will be available on the company website under Science and Events & Presentations.